Vitrolife AB
STO:VITR

Watchlist Manager
Vitrolife AB Logo
Vitrolife AB
STO:VITR
Watchlist
Price: 221.4 SEK 4.04% Market Closed
Market Cap: 30B SEK
Have any thoughts about
Vitrolife AB?
Write Note

Intrinsic Value

The intrinsic value of one VITR stock under the Base Case scenario is 139.61 SEK. Compared to the current market price of 221.4 SEK, Vitrolife AB is Overvalued by 37%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VITR Intrinsic Value
139.61 SEK
Overvaluation 37%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Vitrolife AB

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for VITR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about VITR?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Vitrolife AB

Provide an overview of the primary business activities
of Vitrolife AB.

What unique competitive advantages
does Vitrolife AB hold over its rivals?

What risks and challenges
does Vitrolife AB face in the near future?

Has there been any significant insider trading activity
in Vitrolife AB recently?

Summarize the latest earnings call
of Vitrolife AB.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Vitrolife AB.

Provide P/S
for Vitrolife AB.

Provide P/E
for Vitrolife AB.

Provide P/OCF
for Vitrolife AB.

Provide P/FCFE
for Vitrolife AB.

Provide P/B
for Vitrolife AB.

Provide EV/S
for Vitrolife AB.

Provide EV/GP
for Vitrolife AB.

Provide EV/EBITDA
for Vitrolife AB.

Provide EV/EBIT
for Vitrolife AB.

Provide EV/OCF
for Vitrolife AB.

Provide EV/FCFF
for Vitrolife AB.

Provide EV/IC
for Vitrolife AB.

Show me price targets
for Vitrolife AB made by professional analysts.

What are the Revenue projections
for Vitrolife AB?

How accurate were the past Revenue estimates
for Vitrolife AB?

What are the Net Income projections
for Vitrolife AB?

How accurate were the past Net Income estimates
for Vitrolife AB?

What are the EPS projections
for Vitrolife AB?

How accurate were the past EPS estimates
for Vitrolife AB?

What are the EBIT projections
for Vitrolife AB?

How accurate were the past EBIT estimates
for Vitrolife AB?

Compare the revenue forecasts
for Vitrolife AB with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Vitrolife AB and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Vitrolife AB against its competitors.

Analyze the profit margins
(gross, operating, and net) of Vitrolife AB compared to its peers.

Compare the P/E ratios
of Vitrolife AB against its peers.

Discuss the investment returns and shareholder value creation
comparing Vitrolife AB with its peers.

Analyze the financial leverage
of Vitrolife AB compared to its main competitors.

Show all profitability ratios
for Vitrolife AB.

Provide ROE
for Vitrolife AB.

Provide ROA
for Vitrolife AB.

Provide ROIC
for Vitrolife AB.

Provide ROCE
for Vitrolife AB.

Provide Gross Margin
for Vitrolife AB.

Provide Operating Margin
for Vitrolife AB.

Provide Net Margin
for Vitrolife AB.

Provide FCF Margin
for Vitrolife AB.

Show all solvency ratios
for Vitrolife AB.

Provide D/E Ratio
for Vitrolife AB.

Provide D/A Ratio
for Vitrolife AB.

Provide Interest Coverage Ratio
for Vitrolife AB.

Provide Altman Z-Score Ratio
for Vitrolife AB.

Provide Quick Ratio
for Vitrolife AB.

Provide Current Ratio
for Vitrolife AB.

Provide Cash Ratio
for Vitrolife AB.

What is the historical Revenue growth
over the last 5 years for Vitrolife AB?

What is the historical Net Income growth
over the last 5 years for Vitrolife AB?

What is the current Free Cash Flow
of Vitrolife AB?

Discuss the annual earnings per share (EPS)
trend over the past five years for Vitrolife AB.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Vitrolife AB

Current Assets 2.1B
Cash & Short-Term Investments 925m
Receivables 708m
Other Current Assets 477m
Non-Current Assets 14.8B
Long-Term Investments 54m
PP&E 391m
Intangibles 14.2B
Other Non-Current Assets 154m
Current Liabilities 724m
Accounts Payable 190m
Accrued Liabilities 190m
Other Current Liabilities 344m
Non-Current Liabilities 3B
Long-Term Debt 1.9B
Other Non-Current Liabilities 1.1B
Efficiency

Earnings Waterfall
Vitrolife AB

Revenue
3.6B SEK
Cost of Revenue
-1.5B SEK
Gross Profit
2.1B SEK
Operating Expenses
-5.6B SEK
Operating Income
-3.6B SEK
Other Expenses
-249m SEK
Net Income
-3.8B SEK

Free Cash Flow Analysis
Vitrolife AB

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q3 2024, Vitrolife Group achieved a sales growth of 7% in local currencies, reaching SEK 867 million. Notably, consumables surged by 13%, and Genetic Services in North America recorded a 9% growth. Gross margin improved to 58.6%, while EBITDA margin remained stable at 33.4%. Year-to-date, organic growth stands at 4%, with EBITDA rising to SEK 888 million. For the long-term, the company targets annual organic revenue growth above 10% and aims to maintain an EBITDA margin above 33%. Despite some challenges in their genetic kits division, overall progress is positive, indicating a path toward sustainable growth.

What is Earnings Call?
Fundamental Scores

VITR Profitability Score
Profitability Due Diligence

Vitrolife AB's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Exceptional 3-Years Revenue Growth
Positive Revenue Growth Forecast
39/100
Profitability
Score

Vitrolife AB's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

VITR Solvency Score
Solvency Due Diligence

Vitrolife AB's solvency score is 77/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Short-Term Solvency
77/100
Solvency
Score

Vitrolife AB's solvency score is 77/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VITR Price Targets Summary
Vitrolife AB

Wall Street analysts forecast VITR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VITR is 272.85 SEK with a low forecast of 252.5 SEK and a high forecast of 294 SEK.

Lowest
Price Target
252.5 SEK
14% Upside
Average
Price Target
272.85 SEK
23% Upside
Highest
Price Target
294 SEK
33% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for VITR?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for VITR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

VITR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Vitrolife AB Logo
Vitrolife AB

Country

Sweden

Industry

Biotechnology

Market Cap

30.1B SEK

Dividend Yield

0.45%

Description

Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 427 full-time employees. The company went IPO on 2001-06-26. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. The company also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The firm is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.

Contact

VASTRA GOTALANDS
Goeteborg
Gustaf Werners Gata 2
+46317218000.0
www.vitrolife.com

IPO

2001-06-26

Employees

427

Officers

CEO & President
Ms. Bronwyn Brophy O´Connor
Chief Financial Officer
Mr. Patrik Tolf
Senior Vice President of Technologies
Mr. Claus Bisgaard
Vice President Strategy & Corporate development
Guillermo Ferrando
Senior Vice President of Sales & Marketing
Olivia Natens
Acting Senior Vice President of HR & Sustainability
Frank Pettersson
Show More
Senior Vice President of Consumables
Mr. Rickard Ericsson
Senior Vice President Genetic Services
Ricardo Capella
Show Less

See Also

Discover More
What is the Intrinsic Value of one VITR stock?

The intrinsic value of one VITR stock under the Base Case scenario is 139.61 SEK.

Is VITR stock undervalued or overvalued?

Compared to the current market price of 221.4 SEK, Vitrolife AB is Overvalued by 37%.

Back to Top